Presenting at the Sachs 10th Annual Oncology Forum

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, is pleased to announce that its Chief Financial Officer, Sath Nirmalananthan, will be presenting, and taking part in a panel discussion, at the Sachs 10th Annual Oncology Innovation Forum taking place on the 31st May 2024, at the beginning of the ASCO meeting.

Sath will be participating in the "Advanced Immunotherapies Panel: Cell Therapies & Cancer Vaccines", alongside other companies including AstraZeneca, BTIG and Lumanity. The panel will discuss the current and future role of cell therapies and cancer vaccines and take place from 11:40am - 12:30pm CDT.

Sath has also been invited to give a company presentation, taking place from 1:20pm - 1:40pm CDT at Track B, Sinclair Ballroom, where he will discuss the ongoing Phase 2 SCOPE trial, investigating its cancer vaccine, SCIB1, in combination with checkpoint inhibitors (CPIs) in advanced melanoma and early data from the ongoing Phase 1/2 ModiFY trial with patients receiving Modi-1 as a monotherapy in a range of hard-to-treat solid tumours, which has shown good T cell responses, safety and tolerability.

Sath Nirmalananthan, Chief Financial Officer and Director of Scancell, said: "I am pleased to be invited to participate in both the panel discussion and to present details from our ongoing Phase 2 SCOPE trial and MofiFy study at this esteemed Forum. The program is focused on the latest innovation in IO targets and modalities, and I am also looking forward to highlighting the potential of our proprietary antibody technology platform and our innovative cancer vaccines, and to showcase the great work Scancell is making in this field."

If you would like to arrange a meeting at the Forum, please contact commercial.enquiries@scancell.co.uk.